Neuraxis announces pricing of initial public offering

Carmel, ind., aug. 09, 2023 (globe newswire) -- neuraxis, inc. (nyse american: nrxs) (“neuraxis” or the “company”), a medical technology company commercializing neuromodulation therapies that address chronic and debilitating conditions in children and adults, today announced the pricing of its underwritten initial public offering of 1,098,667 shares of common stock at an initial public offering price of $6.00 per share. the gross proceeds from the offering, before underwriting discounts and commissions and estimated offering expenses payable by the company, are expected to be approximately $6,592,000. in addition, the company has granted the underwriters a 45-day option to purchase up to 164,800 additional shares of common stock at the initial public offering price, less the underwriting discount.
NRXS Ratings Summary
NRXS Quant Ranking